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Abstract
Introduction: Calcitonin, the best known marker for medullary thyroid cancer (MTC), has several laboratory limitations which limit its use
in the routines of non-specialized laboratories. Procalcitonin, the precursor of calcitonin, is free from these drawbacks.
The aim of this study was to compare calcitonin and procalcitonin levels in MTC patients with active disease or in remission, and in
patients with non-toxic nodular goiter (NTNG).
Material and methods: Forty-three serum samples, obtained from 40 patients (6 MTC active disease patients, 23 MTC patients in remis-
sion, and 11 NTNG patients), were tested for calcitonin and procalcitonin levels. The levels of both markers were measured in 2 MTC
patients with active disease before and after surgery. One was re-operated due to neck relapse, the other one due to liver metastases.
Results: Both procalcitonin and calcitonin levels were considerably higher in all MTC patients with the active disease. In two re-operated
patients, the levels of both markers decreased after surgery but remained above the reference range. In the remission group of MTC
patients, 18 had both markers within the reference range, 2 had slightly elevated calcitonin, and 3 patients exhibited both markers slightly
increased. In the NTNG group, all but one patient had normal procalcitonin and calcitonin levels. Analysis revealed a significant correla-
tion between procalcitonin and calcitonin levels (r = 0.7383; p < 0.0001).
Conclusions: Procalcitonin has a similar distribution of values as calcitonin and may be used for evaluation of MTC status in some situa-
tions when accurate CT estimation is not achievable. (Pol J Endocrinol 2010; 61 (5): 430–436)
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Streszczenie
Wstęp: Kalcytonina jest najbardziej znanym i bardzo czułym markerem raka rdzeniastego tarczycy (MTC, medullary thyroid cancer), nie-
mniej, jej oznaczanie nie należy do najłatwiejszych co jest wadą dla niewyspecjalizowanych laboratoriów. Prokalcytonina, prekursor
kalcytoniny jest łatwiejsza w oznaczeniu. Celem pracy było porównanie stężeń kalcytoniny i prokalcytoniny u pacjentów z MTC wykazu-
jących aktywną postać choroby lub będących w remisji oraz u pacjentów z wolem guzowatym nietoksycznym (NTNG, non-toxic nodular
goiter).
Materiał i metody: Czterdzieści trzy próbki surowicy pobrano od 40 pacjentów (6 z aktywną postacią MTC, 23 z MTC w stadium remisji
i 11 z NTNG) i zmierzono stężenia obu markerów. U 2 chorych z aktywnym MTC badania wykonano przed i po zabiegu operacyjnym.
Jeden z nich był reoperowany z powodu wznowy na szyi, drugi miał przerzuty do wątroby.
Wyniki: Stężenia prokalcytoniny i kalcytoniny były znacznie podwyższone u wszystkich chorych z aktywną postacią MTC. U dwóch
reoperowanych chorych stężenia obu markerów obniżyły się po operacji, ale utrzymywały się nadal powyżej normy. W grupie pacjentów
w stadium remisji MTC 18 miało stężenie obu markerów w granicach normy, u 2 stwierdzono nieznacznie podwyższone stężenie kalcy-
toniny, a u 3 nieznacznie podwyższone stężenie obu markerów. W grupie chorych z NTNG, wszyscy chorzy z wyjątkiem jednego mieli
normalne stężenia prokalcytoniny i kalcytoniny. Analiza statystyczna wykazała znamienną korelację stężeń prokalcytoniny i kalcytoniny
(r = 0,7383; p < 0,0001).
Wnioski: Prokalcytonina ma podobny rozkład stężeń, co kalcytonina i obserwuje się znamienną korelację stężeń obu markerów. Może
być ona wykorzystana do oceny chorych z MTC w sytuacjach kiedy stężenie CT jest niemożliwe do oznaczenia.
(Endokrynol Pol 2010; 61 (5): 430–436)
Słowa kluczowe: prokalcytonina, kalcytonina, rak rdzeniasty tarczycy, marker diagnostyczny
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Introduction
Calcitonin (CT) is a 32 amino acid peptide hormone
physiologically produced by C-cells in the thyroid
gland. CT is the best known specific marker for medul-
lary thyroid cancer (MTC). MTC is a relatively rare dis-
ease, accounting for 3–5% of thyroid cancers, but mor-
tality is higher than with differentiated thyroid cancer.
Baseline or stimulated CT levels of more than 100 ng/mL
are observed in almost all cases of MTC [1]. As a general
rule, patients who reach undetectable serum CT levels
soon after surgery are those with the best prognosis [10,
11]. CT measurement is recommended in thyroid nod-
ular goiter for early detection of MTC or C-cell hyper-
plasia [2–4].
Some limitations of CT use may be noted as in-
creased CT concentration is also observed in other dis-
eases such as renal failure, other neuroendocrine tu-
mours, C-cell hyperplasia, some leukaemias, small cell
carcinoma of the lung, breast cancer, pancreatic can-
cers, hyperparathyroidism, and autoimmune thyroidi-
tis [5–9]. CT is rapidly broken down by serum proteas-
es, which may lead to errors — false low or false nega-
tive results — if samples are not processed quickly [7].
Also, normalization of CT serum level after surgery does
not always signal definitive cure of MTC [10, 11].
There are various (at least seven) immunoreactive
isoforms of CT, which could give inaccurate results [12].
CT has a biphasic and concentration-dependent half-
life at physiological and increased levels [6]. Addition-
ally, dual site antibody-based immunoassays are com-
monly used in clinical laboratories to quantify the CT
serum concentrations as a specific and sensitive mark-
er of MTC. Heterophilic antibodies can interfere with
these assays, leading to false results of CT levels [13].
A high-dose hook effect may give false low results for
several tumour markers, such as PSA, CA 19-9, CA 125,
and others [14]. This effect has also been reported for
CT and could be responsible for false low results of cal-
citonin measurements [15, 16]. In contrast, some sub-
stances have been reported to produce false high CT
levels. It has been demonstrated that high levels of vi-
tamin C, urea, and creatine could cause false high lev-
els of CT when measured by RIA [17].
The 116 amino acid precursor of CT, procalcitonin
(PCT), is free from these limitations. It is a product of
the CALC-I gene and consists of a centrally located cal-
citonin and two flanking peptides: N-terminal region
(a 57 amino acid peptide) and katacalcin (a 21 amino
acid peptide), connected by peptidyl glycine amidat-
ing mono-oxygenase [18]. In healthy people, regular
enzymatic processing and further cleavage of PCT, oc-
curring only in C-cells, produces mature CT [19]. In the
presence of bacterial infection or sepsis, the extrathy-
roid transcription of the CALC-I gene is unblocked. An
elevated plasma level of PCT is an early marker of bac-
terial and fungal infection or sepsis [20]. It is related to
disease severity and inversely related to outcome and
treatment response.
In contrast to CT, PCT has a concentration-indepen-
dent half-life and excellent in vitro stability in serum or
plasma [21, 22]. Renal secretion is not a major pathway
of PCT elimination; therefore, renal failure does not affect
the PCT levels [22]. PCT measurement is more available
than CT measurement in many hospital laboratories.
Considering all these facts, we would like to evalu-
ate PCT utility as a potential marker for MTC. For this
aim, we compared calcitonin and procalcitonin levels
in our MTC patients (with active disease or in remis-
sion) and in non-toxic nodular goiter patients (NNTG)
as a control group.
Material and methods
Blood was collected aseptically by venipuncture, and
serum was separated from the clot as soon as possible.
The samples were stored frozen at –200C.
Forty-three serum samples were obtained from
40 patients. Data are shown in Table I.
Three groups of patients were enrolled in the study:
1. MTC active disease patients: (Table I, samples 1–9)
n = 6, mean age 48.2; 5 females, 1 male. Four of them
had disseminated disease (Table I, samples 6–9). PCT
and CT levels were measured twice in one patient
(PU) (Table I, samples 1 and 2): first — one day be-
fore the second operation, and next — three weeks
after re-operation. She was re-operated due to the
local neck recurrence. Liver metastases were excised
in another patient (MA) with disseminated MTC
(Table I, samples 3–5). This patient’s blood was ex-
amined three times: the first time — the day before
surgery, and then twice — two weeks and three
months following resection of liver metastases.
2. Patients with MTC in remission: (Table I, samples
10–32) n = 23, mean age 56.1; 17 females and 6 males.
Patients underwent radical surgery (resection R0)
and were disease-free in clinical and imaging exam-
inations. Their recent CT level remained within the
reference range and was measured in an out-patient
department.
3. NTNG patients whose diagnosis was confirmed by
histopathology: (Table I, samples 33–43) n = 11,
mean age 49.5; 10 females and 1 male.
All MTC patients underwent total thyroidectomy
and lymphadenectomy. The final diagnosis was estab-
lished by histopathology supported by immunohis-
tochemistry (to detect the presence of CT). Lymph node
dissection was performed in four compartments: cen-
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Table I. Patients involved in the study, CT and PCT levels, clinical diagnosis
Tabela I. Pacjenci zakwalifikowani do badania, stężenia CT i PCT, rozpoznanie kliniczne
Patient Sample Age Gender PCT level CT level Clinical diagnosis
(No) (years) [ng/mL]  [pg/mL]
PU 1 47 Female 10.16 1708 MTC with lymph node metastases before operation
PU 2 47 Female 0.32 63.2 MTC with lymph node metastases after operation
MA 3 28 Female 6.67 2456 MTC before resection of liver metastases
MA 4 28 Female 2.92 995 MTC following resection of liver metastases: 2 weeks later
MA 5 28 Female 4.1 1441 MTC following resection of liver metastases: 3 months later
PB 6 49 Female 0.63 236 Disseminated MTC
MA 7 37 Female 5.52 2010 Disseminated MTC
CB 8 65 Female 0.76 159 Disseminated MTC
SZ 9 63 Male 1.48 238 Disseminated MTC
BJ 10 67 Female  < 0.1 13.3 MTC in remission
TG 11 63 Male  < 0.1  < 5 MTC in remission
JS 12 74 Female  < 0.1  < 5 MTC in remission
KB 13 57 Male  < 0.1  < 5 MTC in remission
SS 14 74 Male  < 0.1  < 5 MTC in remission
MM 15 29 Female  < 0.1  < 5 MTC in remission
SA 16 44 Female  < 0.1  < 5 MTC in remission
OB 17 39 Female  < 0.1  < 5 MTC in remission
OA 18 19 Female  < 0.1  < 5 MTC in remission
RU 19 76 Female  < 0.1  < 5 MTC in remission
WB 20 45 Female  < 0.1  < 5 MTC in remission
TL 21 65 Female  < 0.1  < 5 MTC in remission
BB 22 46 Female  < 0.1  < 5 MTC in remission
BM 23 62 Female  < 0.1  < 5 MTC in remission
GB 24 79 Female  < 0.1 7.7 MTC in remission
KJ 25 75 Male  < 0.1  < 5 MTC in remission
KJ 26 63 Male  < 0.1  < 5 MTC in remission
KA 27 36 Female 0.15 9.62 MTC in remission
AW 28 59 Male 0.16 40.6 MTC in remission
NR 29 37 Female  < 0.1  < 5 MTC in remission
SM 30 56 Female  < 0.1  < 5 MTC in remission
WJ 31 57 Female 0.27 21.9 MTC in remission
KK 32 69 Female  < 0.1  < 5 MTC in remission
WJ 33 42 Female  < 0.1  < 5 NTTG
MG 34 39 Female  < 0.1  < 5 NTNG
DK 35 29 Female 0.12  < 5 NTNG
MI 36 55 Female  < 0.1  < 5 NTNG
ŁW 37 66 Female  < 0.1  < 5 NTNG
KW 38 63 Male  < 0.1  < 5 NTNG
DE 39 47 Female 0.28 10.1 NTNG
HC 40 65 Female  < 0.1  < 5 NTNG
NZ 41 46 Female  < 0.1  < 5 NTNG
DA 42 46 Female  < 0.1  < 5 NTNG
NZ 43 46 Female  < 0.1  < 5 NTNG
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tral, both lateral ones, and upper mediastinum. This
approach was consistent with the guidelines of the As-
sociation of Polish Surgeons and the Polish Society of
Oncological Surgery [23]. Post-operatively, all MTC
patients received substitutive doses of levothyroxine to
remain euthyroid and were followed up in our out-pa-
tient department.
All NTNG patients underwent total thyroidectomy
without lymphadenectomy.
Patients with any signs of bacterial or fungal infec-
tion, renal failure, or other carcinomas were excluded
from the study.
Laboratory examination
The frozen sera (–20°C) were taken to the laboratory
unit and assayed for CT and PCT levels.
CT measurement
CT level was measured by the DiaSorin LIAISON® Cal-
citonin Assay (DiaSorin Inc- USA). It is a one-step sand-
wich chemiluminescence immunoassay (CLIA) intend-
ed for quantitative determination of CT in human se-
rum. Affinity-purified mouse antibody to the synthetic
human CT is coated to the solid phase. The second af-
finity-purified mouse antibody is conjugated to an iso-
luminol derivative. During incubation, CT binds to the
solid phase and is subsequently bound by isoluminol
conjugated antibody. Following incubation, the un-
bound material is removed with a wash cycle. The start-
er reagents are then added and a flash chemilumines-
cent reaction is initiated. The light signal is measured
by a photomultiplier as relative light units (RLU) and is
proportional to the concentration of CT present in cali-
brators, controls, or samples. CT reference range is
0–5.5 pg/mL for women and 0–18.9 pg/mL for men.
PCT measurement
PCT level was measured by LIAISON BRAHMS PCT
Assay (DiaSorin S.p.A., Italy). It is a sandwich chemilu-
minescence immunoassay. A specific mouse mono-
clonal antibody is coated on magnetic particles (solid
phase) and another monoclonal antibody is linked to
an isoluminol derivative (isoluminol-antibody conju-
gate). During the incubation, PCT present in calibra-
tors — samples or controls — binds to the solid phase
monoclonal antibody, and then the antibody conjugate
reacts with PCT already bound to the solid phase. After
incubation, the unbound material is removed with
a wash cycle. Subsequently, the starter reagents are add-
ed and a flash chemiluminescence reaction is thus in-
duced. The light signal, and hence the amount of isolu-
minol-antibody conjugate, is measured by a photomul-
tiplier as relative light units (RLU) and is indicative of
PCT concentration present in calibrators — samples or
controls.
PCT reference range is below 0.1 ng/mL.
Statistical analysis
Continuous variables are presented as medians and
quartiles. Nonparametric Kruskall-Walis analysis of vari-
ance was used for inter-group comparisons with Bon-
ferroni corrected Mann-Whitney’s U test used for post-
hoc evaluation. Spearman rank correlation test was used
for correlation assessment. A p value of < 0.05 was cho-
sen as statistical significance threshold.
Results
The three groups did not differ significantly with re-
spect to age, but showed marked differences in both
CT and PCT. Patients with active carcinoma showed
markedly elevated levels of both markers, which were
significantly higher than in patients in remission or the
NTNG control group. Levels of analyzed markers with-
in the studied groups are shown in Table II.
PCT and CT levels were higher in all active MTC
patients — mean PCT 3.5 ng/mL and CT 973 pg/mL
(Fig. 1 and 2).
Table II. Age and CT, PCT levels in the studied groups
Tabela II. Wiek, stężenie CT i PCT w badanych grupach
Active MTC patients MTC patients in remission NTNG p
Age 48 (IQR 37–63) 59 (IQR 44–69) 46 (IQR 42–63) 0.3979
(min.–max. 28–65) (min.–max. 19–79) (min.–max. 29–66)
CT [pg/mL] 973 (IQR 236–2010) 3.12 (IQR 1.27–7.70) 2.66 (IQR 1.56–4.59) 0.0005
(min.–max. 159–2456)*  (min.–max. 0.04–40.60)  (min.–max. 0.12–10.10)
PCT [ng/mL] 3.50 (IQR 0.76–6.67) 0.06 (IQR 0.03–0.08) 0.06 (IQR 0.01–0.10) 0.0005
(min.–max. 0.63–10.16)*  (min.–max. 0.01–0.27)  (min.–max. 0.00–0.28)
*p £ 0.001 in comparison with all other groups. For both parameters, clear cut-off values with no overlap between groups could be established
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In one female patient (PU) (Table I, sample 1), PCT
and CT levels were elevated (PCT — 10.16 ng/mL and
CT — 1708 pg/mL). She was re-operated due to local
neck recurrence; cervical exploration with four-com-
partment lymphadenectomy was performed. Three
weeks after re-operation, PCT and CT and levels de-
creased to 0.32 ng/mL and to 63.2 pg/mL, respectively
(Table I, sample 2). In another patient (MA) (Table I,
sample 3), PCT level was 6.67 ng/mL and CT level was
2456 pg/mL. The patient had resectable liver metastas-
es. Two weeks after surgically radical excision (resec-
tion R1), PCT and CT levels were still above the refer-
ence range, but were much lower. PCT level was
2.92 ng/mL and CT level was 995 pg/mL (Table I, sample 4).
Three months after the operation clinical and imaging
Figure 1. CT levels in the studied groups
Rycina 1. Stężenie CT w badanych grupach
signs of relapse were observed. Relapse was confirmed
by markedly elevated levels of both markers (Table I, sam-
ple 5). In four other patients with disseminated disease,
both markers were significantly elevated (Table I, samples
6–9). In 18 MTC patients in remission, there was no in-
crease in the levels of either marker. Another two patients
from that group (BJ and GB) had slightly elevated CT lev-
els (Table I, samples 10, 24). In three other patients (KA,
AW and WJ), the levels of both markers were slightly in-
creased (Table I, samples 27, 28, 31). In all (Table I, samples
33-43) but one patient (DE) (Table I, sample 39) in the NTNG
group, PCT and CT levels were not elevated.
Correlation analysis showed a significant correlation
between CT and PCT levels in the whole analyzed
group (r = 0.7383; p < 0.0001; Fig. 3 and 4).
Figure 2. PCT levels in the studied groups
Rycina 2. Stężenie PCT w badanych grupach
Figure 3. Correlation of values of PCT and CT levels
Rycina 3. Korelacja wartości stężeń PCT i CT
Figure 4. Correlation of log-transformed values of PCT and CT
levels
Rycina 4. Korelacja wartości stężeń PCT i CT (skala logary-
tmiczna)
435
Endokrynologia Polska/Polish Journal of Endocrinology 2010; 5 (61)
D
O
N
IE
SI
EN
IA
No correlations of either parameter with age were
observed (R = –0.03; p = 0.86 for CT and R = –0.14;
p = 0.39 for PCT). Neither CT nor PCT differed between
males and females (p = 0.78 and 0.69, respectively).
Discussion
CT measurement is the gold standard for the diagnosis
and follow-up of MTC. Some authors have even pro-
posed that the CT level be checked before any thyroid
operation to exclude or reveal MTC [24–26]. The great-
est advantage of CT lies in a good correlation between
clinical stage and CT level. However, as noticed earlier,
CT measurement presents some inadequacies. In these
cases some applications for PCT as an acceptable alter-
native may appear, especially as it is easier to be intro-
duced in laboratories which do not perform many CT
estimations. Its advantages include: a constant and pre-
dictable half-life, absence of isoforms, excellent in-vitro
stability, and analytical consistency between assays [27,
28]. Under normal conditions, the plasma level of PCT
is very low, but it is raised in bacterial and fungal infec-
tions and is, therefore, considered an inflammatory
marker of non-thyroid origin. This study evaluates the
usefulness of PCT as a potential MTC marker. To do
this, we checked the correlation between clinical status
and the levels of PCT and CT. There were four patients
with disseminated MTC (inoperative disease) (Table I,
samples 6–9). In this subgroup, both markers were sub-
stantially increased. PCT, like CT, properly reflected
MTC dissemination in a female patient (PU) (Table I,
samples 1–2); both PCT and CT levels were elevated.
This patient was re-operated due to local neck recur-
rence, and extensive cervical exploration with four-com-
partment lymphadenectomy was performed. A reduc-
tion in the levels of both markers was observed three
weeks later. In another patient (MA) (Table I, samples
3–5), computed tomography revealed metastases locat-
ed in the left lobe of the liver. R1 resection was per-
formed. As in the previous patient, the levels of both
markers decreased post-operatively. Three months lat-
er, both CT and PCT levels were checked once again.
Both markers were considerably increased, and pres-
ently further investigation of a new metastatic site is in
progress.
In disseminated MTC patients, PCT reflected the
active stage of the disease with similar precision as did
CT. Our results were consistent with the findings of
Matzaraki et al. [29], who demonstrated that PCT lev-
els were markedly elevated in cancer patients with gen-
eralized metastatic disease. Twenty-three MTC patients
in post-operative remission were enrolled in our study.
They revealed no metastases in clinical and imaging
examinations, and the most recent CT levels measured
in the out-patient department were not increased. PCT
and CT levels, measured for the study, were not in-
creased in 18 patients, while PCT alone was not in-
creased in 20 patients. This suggests that PCT could be
used as a marker in the follow-up of MTC patients.
Eleven patients operated for NTNG were included
in the study as a control group. We found no increase
in the levels of PCT and CT in these patients, except
slightly elevated PCT and CT levels in one patient (DE)
before routine thyroidectomy (Table I, sample 39). This
suggests that PCT is specific enough to serve as a mark-
er in MTC patients.
Conclusions
Procalcitonin has a similar distribution of values as cal-
citonin may be used for evaluation of MTC status in
some situations when accurate CT estimation is not
achievable.
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